Further supporting the investigation of chemokine inhibitors, recent findings from the COMBAT study highlight the effectiveness of the CXCR4 antagonist BL-8040 combined with pembrolizumab and chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC) (104). The gene discussed is CXCR4; the disease is pancreatic ductal adenocarcinoma.